Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
暂无分享,去创建一个
[1] K. Asplund. Review: Antiplatelet therapy prevents occlusive vascular events in high-risk patients , 2002, ACP Journal Club.
[2] Peter Sandercock,et al. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.
[3] A. Algra,et al. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.
[4] Deepak L. Bhatt,et al. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. , 2000, JAMA.
[5] J. Wittes,et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.
[6] P. Wolf,et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.
[7] R Brian Haynes,et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial , 1999, The Lancet.
[8] C. Sudlow,et al. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. , 2000, Stroke.
[9] J. Danesh,et al. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial , 2000, The Lancet.
[10] C Warlow,et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. , 2000, Stroke.
[11] Zheng-Ming Chen,et al. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.
[12] J. Welch. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. , 1999, European heart journal.
[13] S. Pocock,et al. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .
[14] M. Kaste,et al. Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts. , 1996, Stroke.
[15] R. Collins,et al. Article makes simple errors and could cause unnecessary deaths , 2002, BMJ : British Medical Journal.
[16] J. Slattery,et al. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[17] David P Miller,et al. Long‐Term Protection from Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade with Percutaneous Coronary Intervention , 1998 .
[18] B. Massie. Antithrombotic therapy in heart failure: new perspectives , 2000 .
[19] G. FitzGerald,et al. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. , 1987, Blood.
[20] F. Ferris. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. , 1992, JAMA.
[21] G. Davı̀,et al. Clinical pharmacology of platelet cyclooxygenase inhibition. , 1985, Circulation.
[22] M. Galanski,et al. Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease , 1994, The clinical investigator.
[23] Hans-Christoph Diener,et al. European Stroke Prevention Study 2. Efficacy and safety data. , 1997, Journal of the neurological sciences.
[24] N. Campbell,et al. Secondary prevention clinics for coronary heart disease: randomised trial of effect on health , 1998, BMJ.
[25] Rose Anne Kenny,et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community , 1998, The Lancet.
[26] E. Schryver. Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin , 2000 .
[27] F. Violi,et al. Effect of Picotamide on the Clinical Progression of Peripheral Vascular Disease A Double‐Blind Placebo‐Controlled Study , 1993, Circulation.
[28] D. Gilligan,et al. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. , 2000, The American journal of cardiology.
[29] R. Stafford,et al. Aspirin use is low among United States outpatients with coronary artery disease. , 2000, Circulation.
[30] M. Lavezzari,et al. Indobufen in the Prevention of Thromboembolic Complications in Patients With Heart Disease A Randomized, Placebo‐Controlled, Double‐Blind Study , 1993, Circulation.
[31] 抗栓临床试验协作组. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2004 .
[32] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[33] D. Singer,et al. Recent national patterns of warfarin use in atrial fibrillation. , 1998, Circulation.
[34] B. Henderson,et al. Aspirin use and chronic diseases: a cohort study of the elderly. , 1989, BMJ.
[35] N. Edvardsson,et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris , 1992, The Lancet.
[36] R. More,et al. Antiplatelet rather than anticoagulant therapy with coronary stenting , 1997, The Lancet.
[37] V. Fuster,et al. Low-dose aspirin and stroke. "It ain't necessarily so". , 1992, Stroke.
[38] Colin Baigent,et al. Premature cardiovascular disease in chronic renal failure , 2000, The Lancet.
[39] J. Herbert,et al. The Antiaggregating and Antithrombotic Activity of Ticlopidine Is Potentiated by Aspirin in the Rat , 1996, Thrombosis and Haemostasis.
[40] Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy , 1994, BMJ.
[41] S. Hernández-Díaz,et al. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. , 2001, British journal of clinical pharmacology.
[42] C. Patrono,et al. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. , 1989, Trends in pharmacological sciences.
[43] G. Rasmanis,et al. EFFECTS OF INTERMITTENT TREATMENT WITH ASPIRIN ON THROMBOXANE AND PROSTACYCLIN FORMATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION , 1988, The Lancet.
[44] M. Thun,et al. Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.
[45] David Schultz,et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.
[46] Leandro Provinciali,et al. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .
[47] R. Collins,et al. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.
[48] G. Lip,et al. Original papers , 2013 .
[49] Radcliffe Infirmary,et al. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients , 1994, BMJ.
[50] A. Salam,et al. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease , 2001, Current controlled trials in cardiovascular medicine.
[51] M. Pfisterer,et al. Safe use of platelet GP IIb/IIIa inhibitors. , 1998, American heart journal.
[52] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[53] B. Norrving,et al. Low-dose aspirin and stroke. , 1993, Stroke.
[54] J. Colwell. Aspirin Therapy in Diabetes , 1997, Diabetes Care.
[55] C. Heeschen,et al. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists , 2000, The Lancet.